Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00174811 · ClinicalTrials.gov registry record · Phase 3
Comparative Study to Evaluate the Efficacy and Safety of Telithromycin Given Once Daily Versus Cefuroxime Axetil Given Twice Daily in Children With Middle Ear Infections
A Phase 3 study, sponsored by Sanofi.
- Terminated
- Registry status
- Phase 3
- Development phase
- 639
- Enrollment target
NCT00174811 is a Phase 3 study that was terminated before completion, run by Sanofi. The registered enrollment target is 639 participants.
The verdict
NCT00174811, a Phase 3 study, was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 639 participants
- Enrollment target
Study Summary
The clinical activity of telithromycin vs. cefuroxime in children with acute infections of the middle ear, ages 6 months to 59 months old will be studied.
Interventions
- DRUG telithromycin (HMR3647)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 639 participants |
| Start Date | 2005-06 |
| Est. Completion | 2006-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00174811
The ClinicalTrials.gov registry entry for NCT00174811 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 639 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which telithromycin (HMR3647) is the first listed.
NCT00174811 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00174811 about?
NCT00174811 is a clinical study titled "Comparative Study to Evaluate the Efficacy and Safety of Telithromycin Given Once Daily Versus Cefuroxime Axetil Given Twice Daily in Children With Middle Ear Infections". The clinical activity of telithromycin vs. cefuroxime in children with acute infections of the middle ear, ages 6 months to 59 months old will be studied.
What is the current status of trial NCT00174811?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 639 participants. The study started on 2005-06. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00174811?
The interventions under investigation include: telithromycin (HMR3647) (DRUG).
Who is sponsoring clinical trial NCT00174811?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.